Session 7: Cardiology I and II Answer Explanations
|
|
- Barnard Butler
- 6 years ago
- Views:
Transcription
1 Session 7: Cardiology I and II Answer Explanations Cardiology I 1. Answer A: Intravenous heparin 4000-unit intravenous bolus, followed by a 1000-unit/hour continuous infusion. The NSTE-ACS guidelines recommend the use of one anticoagulant during an acute event. Enoxaparin, unfractionated heparin, and bivalirudin are all recommended as class I agents for the invasive management of NSTE-ACS. However, fondaparinux (Answer C) is not optimal because increased risk of catheter-related thrombosis has been associated with fondaparinux use in the catheterization laboratory. The NSTE-ACS guidelines advise the use of additional heparin if fondaparinux was chosen as an initial anticoagulant when the patient underwent intervention, whereas the PCI guidelines give fondaparinux a class III or harmful recommendation. Of the remaining three options, unfractionated heparin (Answer A) is preferred because of its rapid clearance. Both enoxaparin (Answer B) and bivalirudin (Answer D) are appropriate options but would need to be dose adjusted, given this patient s CrCl of <30 ml/minute. Dosages listed in Answer B and Answer D would be appropriate options for patients with a normal CrCl, however. i. Levine GN, Bates ER, Blankenship JC, et al ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124: ii. Amsterdam EA, Wenger NK, Brindis RG, et al ACC/AHA guideline for the 2. Answer A: Eptifibatide 180-mcg/kg double bolus with a 1-mcg/kg/minute infusion. This patient is experiencing progression of ischemia, as evidenced by his rise in troponin and unrelieved chest pain. Glycoprotein inhibitors, which inhibit the final common pathway of platelet aggregation, provide a reduction in the composite of death and myocardial infarction (MI) and a need for revascularization, especially in high-risk patients who have not been pretreated with a P2Y12 receptor antagonist and in those receiving unfractionated heparin. This patient would be a good candidate at this time for this type of antiplatelet therapy because no loading dose of P2Y12 receptor antagonist has been given and because the anticoagulant used was unfractionated heparin. Of the three available glycoprotein inhibitors, eptifibatide (Answer A) is dosed correctly for a reduced creatinine clearance, which calls for a 50% reduction in infusion with a creatinine clearance below 50 ml/minute. Tirofiban (Answer B) requires a 50% reduction in infusion when the CrCl falls below 30 ml/minute, so the dosing in Answer B is inappropriate in this setting. Abciximab (Answer C) is not appropriate for the medical management of ACS in patients who are not undergoing
2 catheterization, although it is the only glycoprotein inhibitor that is not renally cleared. Rivaroxaban (Answer D) was studied in the ATLAS ACS 2-TIMI 51 trial as add-on therapy to standard therapy in ACS; however, this treatment strategy was used not in the acute phase of ACS treatment. Patients were randomly assigned an average of 4.6 days after ACS. Because of a 3-fold increase in major bleeding, this anticoagulant strategy has not been approved by the U.S. Food and Drug Administration and would be inappropriate. i. Amsterdam EA, Wenger NK, Brindis RG, et al ACC/AHA guideline for the ii. Levine GN, Bates ER, Blankenship JC, et al ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124: iii. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366: Answer C: Aspirin 81 mg indefinitely plus clopidogrel 75 mg daily for 12 months. The choice of which P2Y12 receptor antagonist to use in the ACS setting depends on patient presentation and contraindications and on whether PCI is involved. The 2014 NSTE-ACS guideline gives a class I recommendation for clopidogrel, ticagrelor, and prasugrel in the ACS setting in patients undergoing PCI. This patient is 79 years old, and the age-related caution with using prasugrel in this age group is to generally avoid the drug unless the patient has diabetes or a history of MI. Therefore, Answer A and Answer D are inappropriate for this patient. Although the loading dose of aspirin is generally mg in the acute setting, current guidelines state that it is reasonable to use lower doses of aspirin (i.e., 81 mg) in preference to higher doses (i.e., 325 mg) at the time of discharge. Furthermore, ticagrelor (Answer B) has a black box warning regarding reduced effectiveness when doses higher than 100 mg daily are used concomitantly. Finally, after DES placement in an ACS setting, the time recommended for dual antiplatelet therapy is a minimum of 12 months (Answer C). i. Amsterdam EA, Wenger NK, Brindis RG, et al ACC/AHA guideline for the ii. Levine GN, Bates ER, Blankenship JC, et al ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124: Answer D: Give no β-blocker at this time. Administration of β-blocker therapy carries a risk of causing heart failure decompensation, particularly when titrated too quickly or when initiated in patients who are not euvolemic.
3 Although administering β-blockers within the first 24 hours is a performance measure after STEMI, this patient has several risks that would be considered contraindications to initial β- blockade. The clinical condition of this patient suggests he is not euvolemic, and aggressive diuresis should be attempted before initiation of a β-blocker in this patient. In addition, intravenous β-blocker therapy (Answer B) would place this patient at an even greater risk for cardiogenic shock. Answer A and Answer C are not appropriate because the doses are too aggressive for a patient with an EF of 25%. Answer D is the correct choice, although, before discharge, this patient should be re-evaluated for the initiation of low-dose β-blocker therapy. i. Amsterdam EA, Wenger NK, Brindis RG, et al ACC/AHA guideline for the ii. O Gara PT, Kushner FG, Ascheim DD, et al ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e iii. Yancy CW, Jessup M, Bozkurt B, et al ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62: Answer A: Discontinue ticagrelor; go ahead with surgery after 24 hours; continue aspirin. The U.S. guidelines for treating patients undergoing urgent coronary artery bypass grafting (CABG) surgery recommend discontinuing clopidogrel or ticagrelor for at least 24 hours in the setting of urgent CABG. For elective CABG, clopidogrel and ticagrelor should be discontinued for at least 5 days and prasugrel for at least 7 days before surgery. In addition, this patient had a DES placed 6 months ago. Guidelines recommend continuing a P2Y12 inhibitor for patients who had a stent placed less than 12 months ago; for patients at high risk of ischemic events, guidelines recommend continuing aspirin, so Answer A is correct. Answer B and Answer C are incorrect because aspirin should be continued. Answer D is incorrect because the P2Y12 inhibitor should be discontinued for at least 24 hours to minimize the risk of bleeding from CABG. i. Hillis LD, Smith PK, Anderson JL, et al ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task on Practice Guidelines. Circulation 2011;124:e ii. Amsterdam EA, Wenger NK, Brindis RG, et al ACC/AHA guideline for the
4 Cardiology II 6. Answer D: Apixaban 5 mg twice daily indefinitely given a CHA 2 DS 2 VASc score of 4 This patient is 66 years and has diabetes, HFrEF, and vascular disease giving him a CHA2DS2VASc score of 4 that equates to a 9.3% annualized stroke risk and is therefore considered high risk and should be anticoagulated. The American College of Chest Physicians guidelines recommend anticoagulation over aspirin therapy in patients with a CHA2DS2VASc score of > 2. Therefore, the choice of aspirin given a CHA2DS2VASc of 1 (Answer A) would be incorrect. His estimated CrCl is approximately 44 ml/minute. Because he is also taking amiodarone and has a CrCl less than 80 ml/minute, the combination of rivaroxaban with amiodarone is not recommended (Answer B and C). Apixaban (Answer D) does not have the same degree of interaction with amiodarone and it therefore the best option. Additionally, because this patient does not have two or more of the factors that would warrant a dose adjustment in apixaban (age 80 years or older, body weight less than 60 kg, or SCr of 1.5 mg/dl or greater), the appropriate apixaban dose in this patient would be 5 mg twice daily. i. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(suppl):e513S-e575S. ii. Rivaroxaban (Xarelto) prescribing information. Titusville, NJ: Janssen Pharmaceuticals, December iii. Apixaban (Eliquis) prescribing information. Princeton, NJ: Bristol-Myers Squibb, December Answer C: Increase lisinopril to 20 mg once daily to achieve a BP goal of < 140/90 mmhg J.S. has a number of compelling indications that warrant specific anti-hypertensive therapy. She has diabetes and CKD. According to the 2014 evidence based guideline for the management of high blood pressure in adults-report from the panel members appointed to the Eight Joint National Committee (JNC 8), patients with CKD or diabetes should be managed initially with an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACEI) and her blood pressure goal should be < 140/90 mmhg. Therefore making Answers A, B, and D incorrect. Because J.S. is only on 10 mg of lisinopril, increasing the dose to 20 mg would be the most appropriate to help achieve the recommended BP goal of < 140/90 mmhg over adding any additional blood pressure medications.(answer D) i. James PA, Oparil S, Carter BL, et al evidence-based guideline for the management of high blood pressure in adults - report from the panel members appointed to the Eighth Joint National Committee (JNC8). JAMA Available at ii. American Diabetes Association. Standards of medical care in diabetes Diabetes Care 2014;37:S iii. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012;2:341-2.
5 8. Answer A: Initiate amiodarone 400 mg two times a day x 2 weeks and adjust warfarin as needed. T.H is has HFrEF. Propafenone is considered contraindicated in patients with heart failure (Answer C) and should be avoided. While dronedarone may be used in Class I to class III heart failure, given his recent hospitalization for a CHF exacerbation, dronedarone should be avoided (Answer D). Sotalol is not contraindicated in T.H. however the atrial fibrillation guidelines so not recommend its use in patients with heart failure. Therefore, amiodarone (Answer A) is the most appropriate response as it appears safe in this patient population. Additionally, TH will have to have his INR checked more frequently secondary to amiodarone increasing warfarin levels. i. Wann LS, Curtis AB January CT, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Heart Rhythm Society. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127: ii. Multaq (dronedarone) prescribing information. Sanofi-aventis. Bridgewater, NJ Answer B: Initiate atorvastatin 20 mg once daily. B.M. is a candidate for moderate intensity statin therapy secondary to his diabetes and ASCVD risk of 6% (Answer B). Simvastatin at a dose of 20 mg is considered a high intensity statin but B.M. is also taking diltiazem and the maximum recommended dose simvastatin in combination with diltiazem is 10 mg (Answer A). Lovastatin 40 mg once daily is also a moderate intensity but again, this dose exceeds the recommended dose of 20 mg when combined with ditiazem (Answer C). Rosuvastatin does not interact with diltiazem but the dose of 20 mg is considered a high intensity statin (Answer D). i. Stone NJ, Robinson J, Lichtenstein AH, et al ACC/AHA guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation Available at ii. Lovastatin (Mevacor) prescribing information. Merck & Co., INC. Whitehouse Station, NJ. February, iii. Simvastatin (Zocor) prescribing information. Merck & Co., INC. Whitehouse Station, NJ. February, Answer A: NYHA Class II, Stage C. L.W. has a new diagnosis of HFrEF. He has an EF of 30%, rales on exam, distended neck veins, new S3, and rales bilaterally. He does not state that he is limited in doing any of his regular activities but is experiencing shortness of breath while conducting his normal level of activity. Therefore he falls into NYHA functional class II: Symptoms of HF with normal level of activity (Answer A). L.W. also has symptomatic heart failure and would be a Stage
6 C (Answer A). NYHA Class III (Answers B and D) would be incorrect as this patient does not have marked limitations at rest. Stage B (Answer C) would be incorrect as L.W. is experiencing heart failure symptoms and Stage B is for asymptomatic patients with structural heart disease or previous MI, left ventricular remodeling, left ventricular hypertrophy, or asymptomatic valvular disease. i. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guide line. J Card Fail 2010;16:e1-e194. ii. Hunt SA, Abraham WT, Chin MH, et al fo cused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90.
Updates in Therapeutics: 2013 Pharmacotherapy Preparatory Review and Recertification Course
AMERICAN COLLEGE OF CLINICAL PHARMACY Updates in Therapeutics: 2013 Pharmacotherapy Preparatory Review and Recertification Course POSTTEST ANSWERS SESSION 8 Cardiology I 1. Answer B: NTG intravenously
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationGuideline for STEMI. Reperfusion at a PCI-Capable Hospital
MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationTailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI
Tailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI Adel El-Etriby; MD Professor of Cardiology Ain Shams University President of the Egyptian Working Group of Interventional Cardiology
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationADULT CARDIOVASCULAR CLINICAL PRACTICE GUIDELINES
ADULT CARDIOVASCULAR CLINICAL PRACTICE GUIDELINES Risk Intervention Lifestyle Interventions Hypertension Cholesterol Management Recommendations 1. Smoking cessation 2. Maintain ideal weight or weight reduction
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAtrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted.
Patient Name: Diagnosis: Allergies with reaction type: Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Telemetry Medical Telemetry:
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationConsensus Core Set: Cardiovascular Measures Version 1.0
Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More information6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS
PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient
More information2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with American Association for Thoracic Surgery, American
More informationA Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction 1
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationPerioperative Management. Perioperative Management of Cardiovascular Medications
of Cardiovascular Medications Carmine D Amico, D.O. Overview Learning objectives Beta-blockers Statins Alpha-2 agonists Calcium channel blockers ACE inhibitors and ARB s Anticoagulants Antiplatelet agents
More informationAntithrombotic treatment in ACS: what do the guidelines say? Nicolas Danchin, HEGP, Paris France
Antithrombotic treatment in ACS: what do the guidelines say? Nicolas Danchin, HEGP, Paris France Disclosures Research grants: Astra-Zeneca, Merck, Novartis, Pfizer, sanofi-aventis, Servier, The MedCo Fees
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationClinical Case. Management of ACS Based on ACC/AHA & ESC Guidelines. Clinical Case 4/22/12. UA/NSTEMI: Definition
Clinical Case Management of ACS Based on ACC/AHA & ESC Guidelines Dr Badri Paudel Mr M 75M Poorly controlled diabetic Smoker Presented on Sat 7pm Intense burning in the retrosternal area Clinical Case
More informationAcute Coronary Syndrome (ACS) Initial Evaluation and Management
Acute Coronary Syndrome (ACS) Initial Evaluation and Management Symptoms of Possible ACS Chest discomfort with or without radiation to the arm(s), jaw, or epigastrium Short of breath Weakness Diaphoresis
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More informationPradaxa (dabigatran)
Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationAcute Coronary syndrome
Acute Coronary syndrome 7th Annual Pharmacotherapy Conference ACS Pathophysiology rupture or erosion of a vulnerable, lipidladen, atherosclerotic coronary plaque, resulting in exposure of circulating blood
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationMedical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI
Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the
More informationCoronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National Coronary Artery Disease
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More information2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction Developed in Collaboration with American College of Emergency Physicians and Society for Cardiovascular Angiography and
More informationEuropean Heart Journal 2015 doi: /eurheartj/ehv320
European Heart Journal 2015 doi: 10.1093/eurheartj/ehv320 1 2 Clinical implications of high-sensivity troponin assays European Heart Journal 2015 doi: 10.1093/eurheartj/ehv320 Conditions other than Type
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationCABG Surgery following STEMI
CABG Surgery following STEMI Susana Harrington, MS,APRN-NP Cardio-Thoracic Surgery Nebraska Methodist Hospital February 15, 2018 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction:
More information11/4/2017. but cocaine toxicity is complex: Pro thrombotic effects Progressive atherosclerosis Ventricular remodeling
2 Learning Objectives ATRIUM Fall Patient Safety Webinar Cardiology Mythbusters: Vol 1 Brent N. Reed, PharmD, BCPS AQ Cardiology Associate Professor, University of Maryland School of Pharmacy This presentation
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationNon ST Elevation-ACS. Michael W. Cammarata, MD
Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationAspirin Dose for Cardiovascular Indications
PL Detail-Document #280901 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER September 2012 Aspirin Dose
More informationDiagnosis: Allergies with reaction type:
Patient Name: Diagnosis: Allergies with reaction type: ICU Stroke-Ischemic S/P tpa Version 2 5/29/14 This order set is designed to be used with an admission set or for a patient already admitted Nursing
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationThe Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI
The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish
More informationST Elevation Myocardial Infarction
ST Elevation Myocardial Infarction Scott M. Lilly, MD, PhD Assistant Professor Clinical Department of Cardiovascular Medicine The Ohio State University Wexner Medical Center Case Presentation 46 year old
More informationTriple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health
Triple Therapy: A review of the evidence in acute coronary syndrome Stephanie Kling, PharmD, BCPS Sanford Health Objectives 1. Describe how the presented topic impacts patient outcomes. 2. Review evidence
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 2.9: Antiplatelet Drugs Aspirin 75mg Dispersible Tablets Aspirin 300mg Dispersible Tablets Aspirin 300mg Suppositories Clopidogrel 75mg Tablets Dipyridamole
More informationNovel Anticoagulation Therapy in Acute Coronary Syndrome
Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationA Patient with Chest Pain and Atrial Fibrillation
A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationST Elevation Myocardial Infarction
ST Elevation Myocardial Infarction Scott M. Lilly, MD, PhD Assistant Professor Clinical Department of Cardiovascular Medicine The Ohio State University Wexner Medical Center Outline Case Presentation STEMI
More informationCost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib
Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million
More informationConsultation Group: Cardiology Consultants Clinical lead for cardiology: Dr Andrew Hannah. Review Date: Uncontrolled when printed.
NHS Grampian Staff Guidelines For The In-Hospital Management Of Unstable Angina And Non-ST-Segment- Elevation Myocardial Infarction Patients (17 Years And Older) Co-ordinators: Cardiology Specialist Clinical
More informationChest Pain Acute Coronary Syndrome Version 4 4/10/17 This order set is designed to be used with an admission set or for a patient already admitted
Patient Name: Diagnosis: Allergies with reaction type: Chest Pain Acute Coronary Syndrome Version 4 4/10/17 This order set is designed to be used with an admission set or for a patient already admitted
More information(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris
Early aggressive versus initially conservative strategy in elderly patients with non-st- elevation acute coronary syndrome: the Italian randomised trial (ClinicalTrials.gov ID: NCT00510185) Stefano Savonitto,
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationEarly Management of Acute Coronary Syndrome
Early Management of Acute Coronary Syndrome Connie Hess, MD, MHS University of Colorado Division of Cardiology Acute Coronary Syndrome (ACS) A range of conditions associated with sudden imbalance in myocardial
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial
compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A
More information2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary
Journal of the American College of Cardiology Vol. 61, No. 4, 2013 2013 by the American College of Cardiology Foundation and the American Heart Association, Inc. ISSN 0735-1097/$36.00 Published by Elsevier
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationCoronary Artery Disease Clinical Practice Guidelines
Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.
More informationST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department
ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for
More informationNorth Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease
Guidelines on oral antiplatelet therapy in cardiovascular disease This guidance should be considered as one part of the wider therapeutic management of patients. The indication for antiplatelet therapy
More information2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation Thierry Gillebert European Society of Cardiology, Slides kindly provided
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More information2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #204 (NQF 0068): Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationPlatelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor
More informationDr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου
Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου Θεσσαλονίκη, 9/2/2018 Disclosures: None Primary efficacy outcome* (%/year) Antiplatelet Therapy
More informationSTEMI 2014 YAHYA KIWAN. Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital
STEMI 2014 YAHYA KIWAN Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital Aspiration Thrombectomy Manual aspiration thrombectomy is reasonable for patients undergoing primary PCI. I
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationDual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015
Dual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015 Wesam A Alhejily MD FRCPC FACP FACC FSCAI Assistant Professor of Medicine Chief Of Adult Cardiology Consultant
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationAntiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center
Antiplatelets and Anticoagulants Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Mechanism 2 http://www.medicinehack.com/2011/07/virchows-triad.html Mechanism 3 http://drtedwilliams.net/kb/index.php?pagename=coagulation%20cascade
More informationMyth or Real? The Potential Serious Side Effects of Ticagrelor
447 International Journal of Collaborative Research on Internal Medicine & Public Health Myth or Real? The Potential Serious Side Effects of Ticagrelor Wassam EL Din Hadad EL Shafey* Cardiology Department,
More informationLong-Term Management Of the ACS Patient: State-of-the-Art. Kim Newlin, CNS, NP-C, FPCNA Sutter Roseville Medical Center Roseville, CA
Long-Term Management Of the ACS Patient: State-of-the-Art Kim Newlin, CNS, NP-C, FPCNA Sutter Roseville Medical Center Roseville, CA Disclosures I have no disclosures. Case Study 45 y/o male admitted to
More informationThe Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now. Bradley A. Hardin, MD Richard F.
The Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now Bradley A. Hardin, MD Richard F. Otten, MD, FACC Outline Atrial Fibrillation Overview Overview of New Oral Anticoagulants
More informationStudy design: multicenter, randomized, open-label trial following a PROBE design
Subgroup Analysis from the RE-DUAL PCI Trial Dual Antithrombotic Therapy with in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Jonas Oldgren, Philippe Gabriel Steg, Stefan
More informationSafe initiation of DOAC for patients with CAD/PAD already on guideline directed therapy
Administration DOCUMENT PURPOSE This order set may be used for patients diagnosed with stable coronary artery disease (CAD) and/or peripheral artery disease (PAD) who are already being treated with guideline
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationAnticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017
Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation
More information